Biocon gets on DCGI approval for use of CytoSorb to treat COVID-19 patients

Published On: Wednesday, May 27, 2020 | By: Team KnowMyStock

Biocon has received approval from the Drugs Controller General of India (DCGI) for its blood purification device CytoSorb meant for Covid-19 patients. It is a device that reduces pro-inflammatory cytokines levels in confirmed Covid-19 patients admitted to the intensive care unit with confirmed or imminent respiratory failure. Biocon Biologics has been granted the license for emergency use of CytoSorb to treat Covid-19 patients who are 18 years of age or older. The license will be effective until control of the Covid-19 outbreak in the country."CytoSorb is an in-licensed unique device that reduces cytokine storm in critically ill patients and was introduced by Biocon in India in 2013. Since then many patients undergoing organ transplant and sepsis treatment have benefitted from it," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon. In April, the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) of CytoSorb for use in patients with COVID-19 infection.

Closing Bell: Sensex gains 85 points, Nifty at 18755.90

Closing Bell:Sensex gains 418 points, Nifty at 18716.15

MARKET UPDATE: Sensex rose 135 points to 62761, and the NSE Nifty50 moved 40 points higher to 18,600

Closing Bell: Sensex down 223 points, Nifty at 18,563

MARKET UPDATE: Sensex surged over 100 points to trade around 62,962 levels, whereas Nifty50 climbed over 30 points to trade above 18,650 levels

MARKET UPDATE: Sensex gained over 50 points to trade around 63,228 levels, whereas Nifty50 traded marginally above 18,700 levels

MARKET UPDATE: Sensex surged over 150 points to trade around 62,988 levels, whereas Nifty50 gained over 50 points to trade above 18,650 levels

MARKET UPDATE: Sensex traded flat at 62,777 levels, whereas Nifty50 was flat above 18,600 levels

Closing Bell: Sensex up 240 points, Nifty at 18593.85

MARKET UPDATE: Sensex rallied over 300 points, whereas Nifty50 gained over 50 points to trade above 18,600 levels

We are on Telegram!

JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.

Click Here!

Follow Us On:

---